A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/25/3/638/16699375/mdt589.pdf
Reference16 articles.
1. Oesophageal cancer in The Netherlands: increasing incidence and mortality but improving survival;Crane;Eur J Cancer,2007
2. Dutch Cancer Registration2005Survival of esophageal cancer patients in the Netherlands www.cijfersoverkanker.nl/selecties/Dataset_2/img512d09a0bce07 8 September 2013, data last accessed
3. Continuing rapid increase in esophageal adenocarcinoma in England and Wales;Lepage;Am J Gastroenterol,2008
4. Oesophageal carcinoma;Pennathur;Lancet,2013
5. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis;Sjoquist;Lancet Oncol,2011
Cited by 101 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Neoadjuvant radiochemotherapy with cisplatin/5-flourouracil or carboplatin/paclitaxel in patients with resectable cancer of the esophagus and the gastroesophageal junction — comparison of postoperative mortality and complications, toxicity, and pathological tumor response;Langenbeck's Archives of Surgery;2023-11-08
2. The Prognostic Value of Sequential 18F-FDG PET/CT Metabolic Parameters in Outcomes of Upper-Third Esophageal Squamous Cell Carcinoma Patients Treated with Definitive Chemoradiotherapy;World Journal of Nuclear Medicine;2023-09
3. Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial;eClinicalMedicine;2023-07
4. Treatment burden and cost-effectiveness analysis of the neoadjuvant CROSS regimen in esophageal squamous cell carcinoma: a multicenter retrospective study;Diseases of the Esophagus;2023-05-26
5. Geriatric Radiation Oncology: What We Know and What Can We Do Better?;Clinical Interventions in Aging;2023-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3